Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials.

Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials. Eur Heart J. 2014 Sep 01; 35(33):2249-59.

View in: PubMed

subject areas

Aged
Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Anticholesteremic Agents
Azetidines
Clinical Trials, Phase II as Topic
Ezetimibe
Female
Humans
Hyperlipidemias
Lipid Metabolism
Male
Middle Aged
Proprotein Convertase 9
Proprotein Convertases
Randomized Controlled Trials as Topic
Serine Endopeptidases
Treatment Outcome